Compare Equinox Gold Corp. Common Shares (EQX) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinox Gold Corp. Common Shares vs Repligen Corporation Common Stock — how do they compare? Equinox Gold Corp. Common Shares trades at $10.62 (market cap $12.03B), while Repligen Corporation Common Stock trades at $184.78 (market cap $11.31B). The key difference: Equinox Gold Corp. Common Shares and Repligen Corporation Common Stock are close in size by market cap, and Equinox Gold Corp. Common Shares pays a 0.51% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinox Gold Corp. Common Shares for 6 Days and Repligen Corporation Common Stock for 0 Days on average.
| EQX | RGEN | |
|---|---|---|
Market Cap | $12.03B | $11.31B |
Volume | 12,695,148 | 1,216,919 |
Sector | Basic Materials | Health |
52-Week High | $18.76 | $194.57 |
52-Week Low | $8.62 | $102.87 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $12.13B | $11.20B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinox Gold (EQX) trades at $10.85, down 3.12% on the day, with a bearish technical signal from moving averages. The company reported strong 2025 results with $1.82B revenue and $221M net income, and projects significant growth in 2026 to $2.9B revenue. Recent news highlights the completion of the Orla Mining merger, positioning EQX as a major North American gold producer with a path to 2 million ounces of annual production.
The outlook is positive due to transformative growth from the Orla acquisition, increased production guidance, and a 50% dividend hike. Risks include execution of mine expansions and gold price volatility. With a 100% buy rating from one analyst, the stock appears undervalued relative to its growth pipeline, though recent earnings misses warrant monitoring.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinox Gold Corp. Common Shares
Equinox Gold is a gold mining company with operations in the Americas. It produces gold and develops additional mining projects.
Read more on EQX →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
